Explore

Trendline Trendline
Relay Therapeutics Achieves 60% Response Rate in Rare Disease Trial, Surpassing Novartis

Relay Therapeutics Achieves 60% Response Rate in Rare Disease Trial, Surpassing Novartis

Relay Therapeutics Achieves 60% Response Rate in Rare Disease Trial, Surpassing Novartis
Trendline Trendline
BioMarin Faces Setback with Phase 3 Trial Failure in Rare Disease Treatment

BioMarin Faces Setback with Phase 3 Trial Failure in Rare Disease Treatment

BioMarin Faces Setback with Phase 3 Trial Failure in Rare Disease Treatment
Trendline Trendline
Sanofi's Experimental Therapy for AATD Shows Promise in Phase 2 Trial

Sanofi's Experimental Therapy for AATD Shows Promise in Phase 2 Trial

Sanofi's Experimental Therapy for AATD Shows Promise in Phase 2 Trial
Trendline Trendline
Atossa Therapeutics Highlights Potential of (Z)-Endoxifen in Duchenne Muscular Dystrophy

Atossa Therapeutics Highlights Potential of (Z)-Endoxifen in Duchenne Muscular Dystrophy

Atossa Therapeutics Highlights Potential of (Z)-Endoxifen in Duchenne Muscular Dystrophy
Trendline Trendline
OpenBind Launches AI Model for Drug Discovery with Extensive Dataset

OpenBind Launches AI Model for Drug Discovery with Extensive Dataset

OpenBind Launches AI Model for Drug Discovery with Extensive Dataset
Trendline Trendline
IntraBio Begins Phase III Trial for CACNA1A-Related Disorders

IntraBio Begins Phase III Trial for CACNA1A-Related Disorders

IntraBio Begins Phase III Trial for CACNA1A-Related Disorders
Trendline Trendline
Beam Therapeutics Advances DNA Editor BEAM-302 for Alpha-1 Antitrypsin Deficiency

Beam Therapeutics Advances DNA Editor BEAM-302 for Alpha-1 Antitrypsin Deficiency

Beam Therapeutics Advances DNA Editor BEAM-302 for Alpha-1 Antitrypsin Deficiency
Trendline Trendline
Verdiva Bio to Present Preclinical Data on Obesity Drug Candidates at ADA Scientific Sessions

Verdiva Bio to Present Preclinical Data on Obesity Drug Candidates at ADA Scientific Sessions

Verdiva Bio to Present Preclinical Data on Obesity Drug Candidates at ADA Scientific Sessions
Trendline Trendline
FDA Alignment and AI Integration Crucial for Rare Disease Treatment Advancements

FDA Alignment and AI Integration Crucial for Rare Disease Treatment Advancements

FDA Alignment and AI Integration Crucial for Rare Disease Treatment Advancements
Trendline Trendline
Amylyx Pharmaceuticals Publishes Phase 2 Trial Data for AMX0035 in Wolfram Syndrome

Amylyx Pharmaceuticals Publishes Phase 2 Trial Data for AMX0035 in Wolfram Syndrome

Amylyx Pharmaceuticals Publishes Phase 2 Trial Data for AMX0035 in Wolfram Syndrome
Trendline Trendline
Harbour BioMed Unveils Promising Preclinical Data for AI-Enabled Drug LET003 Targeting Obesity

Harbour BioMed Unveils Promising Preclinical Data for AI-Enabled Drug LET003 Targeting Obesity

Harbour BioMed Unveils Promising Preclinical Data for AI-Enabled Drug LET003 Targeting Obesity
Trendline Trendline
Palatin Technologies to List on Nasdaq, Enhancing Market Visibility

Palatin Technologies to List on Nasdaq, Enhancing Market Visibility

Palatin Technologies to List on Nasdaq, Enhancing Market Visibility